VKTX Research and Charts

VKTX - Viking Therapeutics Inc (Healthcare: Biotechnology)

Projected Earnings Date: 2026-05-13 (Delayed quote data 2026-02-10)

Last 28.75	Change ⇓ -0.55 (-1.88%)	Volume 1,916,527
	Open 29.10	High 29.70	Low 28.64

8EMA (Daily) 29.11	40EMA (Daily) 32.02	50EMA (Daily) 32.39	STO (Daily) 25.482	MACD Hist (Daily) -0.014
8EMA (Weekly) 31.340	40EMA (Weekly) 33.32	50EMA (Weekly) 33.89	STO (Weekly) 17.003	MACD Hist (Weekly) -1.235


Company Profile
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.